Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP664692.RAGj-xzO1vsJQ2NClL81a1CWn_hu6BgGvFTXH72ePLxq8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP664692.RAGj-xzO1vsJQ2NClL81a1CWn_hu6BgGvFTXH72ePLxq8130_assertion type Assertion NP664692.RAGj-xzO1vsJQ2NClL81a1CWn_hu6BgGvFTXH72ePLxq8130_head.
- NP664692.RAGj-xzO1vsJQ2NClL81a1CWn_hu6BgGvFTXH72ePLxq8130_assertion wasGeneratedBy ECO_0000203 NP664692.RAGj-xzO1vsJQ2NClL81a1CWn_hu6BgGvFTXH72ePLxq8130_provenance.
- NP664692.RAGj-xzO1vsJQ2NClL81a1CWn_hu6BgGvFTXH72ePLxq8130_assertion wasDerivedFrom befree-20150227 NP664692.RAGj-xzO1vsJQ2NClL81a1CWn_hu6BgGvFTXH72ePLxq8130_provenance.
- NP664692.RAGj-xzO1vsJQ2NClL81a1CWn_hu6BgGvFTXH72ePLxq8130_assertion SIO_000772 21220499 NP664692.RAGj-xzO1vsJQ2NClL81a1CWn_hu6BgGvFTXH72ePLxq8130_provenance.
- NP664692.RAGj-xzO1vsJQ2NClL81a1CWn_hu6BgGvFTXH72ePLxq8130_assertion evidence source_evidence_literature NP664692.RAGj-xzO1vsJQ2NClL81a1CWn_hu6BgGvFTXH72ePLxq8130_provenance.
- NP664692.RAGj-xzO1vsJQ2NClL81a1CWn_hu6BgGvFTXH72ePLxq8130_assertion description "[Sorafenib, a VEGFR inhibitor with activity against RAF kinase, is active against hepatocellular carcinoma (HCC); however, the possible involvement of sorafenib in the EMT remains unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP664692.RAGj-xzO1vsJQ2NClL81a1CWn_hu6BgGvFTXH72ePLxq8130_provenance.